UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/622,725	07/18/2003	Frank Butaric	CRD-0836 DIV I	2936	
27777 PHILIP S. JOH	7590 03/28/2007 FNSON		EXAMINER		
JOHNSON & JOHNSON			MILLER, CHERYL L		
	N & JOHNSON PLAZA WICK, NJ 08933-7003		ART UNIT PAPER NUMBER		
	,		3738		
•				·	
SHORTENED STATUTOR	RY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE		
3 MC	SHTM	03/28/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

				<i>_</i>			
		Application No.	Applicant(s)				
		10/622,725	BUTARIC ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Cheryl Miller	3738				
Period fo	The MAILING DATE of this communication ap or Reply	pears on the cover sheet	with the correspondence address				
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLICHEVER IS LONGER, FROM THE MAILING Insions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. In period for reply is specified above, the maximum statutory period re to reply within the set or extended period for reply will, by statutely received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMU 136(a). In no event, however, mar I will apply and will expire SIX (6) Note, cause the application to become	NICATION. y a reply be timely filed NONTHS from the mailing date of this communicated ABANDONED (35 U.S.C. § 133).				
Status							
1)	Responsive to communication(s) filed on 20 F	February 2007.					
•	This action is FINAL. 2b)⊠ This action is non-final.						
3) 🗌	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under	Ex parte Quayle, 1935 (D.D. 11, 453 O.G. 213.				
Dispositi	on of Claims						
4)⊠	Claim(s) 1-6 is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)	Claim(s) is/are allowed.						
6)⊠	6)⊠ Claim(s) <u>1-6</u> is/are rejected.						
-	Claim(s) is/are objected to.						
8)∐	Claim(s) are subject to restriction and/	or election requirement.					
Applicati	on Papers						
9)	The specification is objected to by the Examin	ier.					
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the						
_	Replacement drawing sheet(s) including the correct						
11)[_]	The oath or declaration is objected to by the E	xaminer. Note the attac	hed Office Action or form PTO-152	2.			
Priority (ınder 35 U.S.C. § 119						
	Acknowledgment is made of a claim for foreig All b) Some * c) None of: 1. Certified copies of the priority documer		C. § 119(a)-(d) or (f).				
	2. Certified copies of the priority documer		n Application No				
	3. Copies of the certified copies of the pri- application from the International Burea	ority documents have be		t ⁻ .			
* <u>{</u>	See the attached detailed Office action for a lis	t of the certified copies i	not received.				
Attachmen	t(s)						
1) Notic	e of References Cited (PTO-892)		w Summary (PTO-413)				
2) Notice 3) Information	No(s)/Mail Date of Informal Patent Application HEDNIMENT						
- ape	r No(s)/Mail Date	о, ұз олы.					

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on January 8, 2007 has been entered.

Response to Arguments

Applicant's arguments with respect to claims 1-6 have been considered but are moot in view of the new ground(s) of rejection.

However, since the Lunn (US 5,476,506) rejection has been maintained, the examiner has responded to the applicant's arguments regarding this reference. The applicant has argued that Lunn's stent does not extend the entire length of the graft. This limitation however has not been claimed. The claim only requires that the graft substantially cover the stent body. Lunn clearly shows in fig.4 for example, a stent (38), of which a graft (10) covers substantially all if not all, of the stent body 38.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-6 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Application/Control Number: 10/622,725

Art Unit: 3738

Claim 1 recites, "graft member attached to and covering substantially of said body". This limitation is unclear and indefinite. It seems that applicant may have intended to claim the graft to cover all of the body, or the majority of the body, or to substantially cover the body, however it is unclear as presently recited. Claims 2-6 depend upon claim 1 and inherit all problems associated with the claim.

Page 3

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-4 are rejected under 35 U.S.C. 102(b) as being anticipated by Lunn (US 5,476,506, cited previously). Lunn discloses a stent graft (fig. 1, 4, 5) comprising a hollow cylindrical radially expandable stent (36, 38, 50, or 52) having a body, two open ends and a longitudinal axis, the body comprising a plurality of interconnected struts (as seen in figs.5a-5d) forming a plurality of diamond shaped cells and a plurality of sinusoidal rings positioned between the cells (see attachment 1), and a graft member (10) attached to and covering the body of the stent (graft seen clearly in fig.4 to cover all of the stent(s)), the graft (10) having a plurality of longitudinally directed pleats (22+24). Lunn discloses the graft (10) attached to the exterior of the stent (36, 38, 50, 52). Lunn discloses a graft (10) made of the materials claimed (col.5, lines 59-67). Lunn discloses the graft (10) attached to the stent (36, 38, 50, or 52) by a staple (col.5, lines 10-14).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 5-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lunn (US 5,476,506, cited previously). Lunn discloses a stent graft substantially as claimed. Lunn however, discloses a balloon expandable stent instead of a self-expanding stent. It would have been obvious to one having ordinary skill in the art at the time the invention was made to have a nitinol or such type of self expanding stent, since self expanding stent materials are know alternatives to balloon expandable stent materials, and also since it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a matter of obvious design choice. *In re Leshin*, 125 USPQ 416.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cheryl Miller whose telephone number is (571) 272-4755. The examiner can normally be reached on Monday-Friday 7:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on (571) 272-4755. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/622,725 Page 5

Art Unit: 3738

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Cheryl Miller

BRUCE SNOW PRIMARY FXAMINER

achment #/ (markedup)
Sheet 3 of 4 5,476,506 20 F16.5A F1G.5B